Log In
Print
BCIQ
Print
Print this Print this
 

EB-1020 SR

  Manage Alerts
Collapse Summary General Information
Company Neurovance Inc.
DescriptionSustained-release formulation of a serotonin, norepinephrine and dopamine reuptake inhibitor that preferentially targets norepinephrine and dopamine
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat adult ADHD
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today